SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders, is sponsoring the National Parkinson Foundation’s (NPF) Caregiver Summit that will be held today in Portland, Oregon. The Caregiver Summit is a daylong event that brings together caregivers from all over the world to share their experiences and everyday strategies for caring for someone with Parkinson’s disease. The Caregiver Summit immediately precedes the 4th World Parkinson Congress, which takes place September 20-23.
“ACADIA is proud to partner with the National Parkinson Foundation in providing caregivers with support, education and access to much-needed resources,” said Steve Davis, ACADIA’s President and Chief Executive Officer. “Caregivers play a vital role in caring for people with Parkinson’s disease – but all too often, their own needs are overlooked. The Caregiver Summit is an important step in better understanding and addressing caregiver needs, and we are gratified to offer our support.”
“At the National Parkinson Foundation, we understand that Parkinson’s disease has a significant impact on people who’ve gotten that diagnosis, as well as on those who care for and about them,” said Vaughn Edelson, NPF’s Director of Education. “The Caregiver Summit is an opportunity for us to offer resources and support to caregivers now and in the future, and we look forward to continued engagement with this important part of the Parkinson’s community.”
ACADIA at 4th World Parkinson Congress
Following the Caregiver Summit, ACADIA will be exhibiting with two booths at the World Parkinson Congress: Booth 700 for healthcare providers and Booth 612, a disease education booth for consumers. In addition, ACADIA will present three scientific posters at the Congress:
- Decreased burden among caregivers of patients with Parkinson’s disease psychosis (PDP) treated with pimavanserin, a selective 5-HT2A inverse agonist (Poster P12.08).
- Caregivers of PDP patients have an increased risk of developing emotional and social distress that is decreased when PDP is treated with pimavanserin (Poster P42.11).
- The safety profile of pimavanserin: Focus on motor symptoms and extrapyramidal-related adverse events in patients with Parkinson’s disease psychosis (PDP) (Poster P35.10).
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.com to which we regularly post copies of our press releases as well as additional information and through which interested parties can subscribe to receive e-mail alerts.
About the National Parkinson Foundation, a division of the Parkinson’s Foundation
The Parkinson’s Foundation is working toward a world without Parkinson’s disease. Formed by the merger of National Parkinson Foundation (NPF) and the Parkinson’s Disease Foundation (PDF) in August 2016, the mission of the Parkinson’s Foundation is to invest in promising scientific research that will end Parkinson’s disease and improve the lives of people with Parkinson’s, and their families, through improved treatments, support and the best care. For more information, visit www.parkinson.org or www.pdf.org, or call (800) 4PD-INFO (473-4636) or (800) 457-6676.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919005267/en/
